-
Sector Analysis
Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the NASH market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026
Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease but occurs in people who drink little or no alcohol, and is a highly progressed form of non-alcoholic fatty liver disease (NAFLD). NASH is becoming increasingly common with the alarming epidemic of obesity and carries the risk for more aggressive liver diseases such as cirrhosis, liver failure, and in some rare instances, hepatocellular...
-
Product Insights
Alcoholic Hepatitis Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Alcoholic Hepatitis Global Clinical Trials Review, H1, 2017" provides an overview of Alcoholic Hepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Alcoholic Hepatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
OpportunityAnalyzer: NASH – Opportunity Analysis and Forecasts to 2026
First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and it is therefore a potentially fatal condition . GlobalData estimates...
-
Product Insights
Alcoholic Hepatitis Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Alcoholic Hepatitis Global Clinical Trials Review, H2, 2016" provides an overview of Alcoholic Hepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Alcoholic Hepatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...